Search Bar & Filters
Found 87 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.
Actively Recruiting
Researchers are studying the impact and burden of three skin conditions moderate or severe alopecia areata, non-segmental vitiligo, and moderate to severe hidradenitis suppurativa. The study includes adolescents and adults and aims to understand how these conditions affect quality of life and daily functioning in a large global population. This is an observational study where participants with each condition will have a single visit for data collection following routine clinical practice. No experimental treatments are given instead, the study gathers information during this one visit to assess disease characteristics and impact. During the visit, participants will complete questionnaires and clinical assessments specific to their condition. These include tools measuring symptom impact, hair loss severity, skin depigmentation, and quality of life related to each disease. This helps researchers better understand the real-world burden of these conditions. Participation involves only this one visit, with no long-term follow-up or additional procedures.
Actively Recruiting
This research aims to compare two surgical approaches for patients experiencing increased intracranial pressure caused by malignant stroke. It investigates whether using a single surgery with an individually molded space-expanding shield can be a viable alternative to the standard decompressive hemicraniectomy followed by a second surgery called cranioplasty. The study is planned as a randomized, controlled, multicenter trial to evaluate these methods in stroke patients aged 18 to under 70. Participants will be randomly assigned to one of two groups. The experimental group will receive decompressive hemicraniectomy with implantation of a space-expanding shield that allows brain swelling while providing protection in a single surgery. The control group will undergo the standard decompressive hemicraniectomy without the shield and later undergo cranioplasty about 90 days after the initial surgery. Follow-up examinations are scheduled at 1 to 7 days, 6 weeks, 3 months, and 6 months after surgery. During the study, participants will undergo evaluations including neurological assessments and imaging to monitor recovery and complications. Researchers will measure outcomes such as the modified Rankin Scale score at 6 months, number of additional surgeries for intracranial pressure control, infections, wound healing, syndrome of the trephined, survival, cosmetic satisfaction, and quality of life. The total duration of participation for each patient is 6 months, with safety and recovery closely monitored throughout.
Actively Recruiting
Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.
Actively Recruiting
Researchers are studying adults with a brain tumour that tests positive for the tumour marker delta-like 3 DLL3, focusing on those whose previous treatments were not successful. This trial aims to find the highest dose of BI 764532, an antibody-like molecule that may help the immune system fight cancer by linking cancer cells and immune T-cells. The study is a phase 1, open-label, dose escalation trial sponsored by Boehringer Ingelheim. Participants receive BI 764532 through intravenous infusions at the start of treatment. If the treatment shows benefit and is well tolerated, it continues, with the number of visits depending on individual response and tolerance. Initial visits include close monitoring for safety. The study does not involve placebo or comparison groups and focuses on escalating doses to determine the maximum tolerated dose. During the study, participants attend regular visits where doctors monitor safety, record any side effects, and check overall health. The main outcome measured is the occurrence of dose-limiting toxicities during the first four weeks of treatment, with secondary measures extending up to 26 months. The study duration and visits vary depending on how participants respond and tolerate the treatment, ensuring careful assessment throughout.
Actively Recruiting
Glucocorticoids are hormones that help control inflammation and regulate the immune system. In children with blood cancers like acute lymphoblastic leukemia ALL and lymphoblastic lymphoma LBL, these hormones are given as medications to quickly reduce cancer cells. However, this treatment can suppress the bodys natural glucocorticoid production, leading to a deficiency that increases infection risks and is hard to detect due to overlapping chemotherapy side effects. This study aims to understand how often and for how long this deficiency occurs in children with these cancers and to identify those at higher risk. The study observes children diagnosed with ALL or LBL who are treated with glucocorticoids for at least 21 consecutive days. Regular low-dose ACTH tests will be performed during and after treatment to assess the bodys natural glucocorticoid production. These tests are done only when children already have venous access and are hospitalized for treatment, minimizing extra burden. The study follows participants from enrollment until three months after their last glucocorticoid dose. Participants will be monitored through these ACTH tests to detect adrenal insufficiency and its duration. The main outcome measured is the occurrence of adrenal insufficiency, with a secondary focus on how long it lasts. The study involves children up to 18 years old and takes place at two childrens hospitals. The goal is to improve understanding and management of glucocorticoid deficiency during and after cancer treatment, with careful attention to the safety and comfort of the children involved.
Actively Recruiting
Researchers are evaluating whether antibiotic treatment is necessary for children with community-acquired pneumonia caused by the bacterium Mycoplasma pneumoniae. This trial compares the effects of a commonly used antibiotic, azithromycin, with a placebo in children aged 3 to 17 years. The study addresses concerns about increasing antibiotic resistance and aims to improve treatment decisions for this common cause of pneumonia in children. Participants are randomly assigned to receive either azithromycin or a placebo for five days. The azithromycin group takes a daily dose of 10mgkg on the first day followed by 5mgkg on days 2 through 5. This randomized, double-blind, placebo-controlled trial takes place across multiple pediatric centers and includes both ambulatory and hospitalized children. The study involves initial screening to confirm Mycoplasma pneumoniae infection using a specific antibody test before starting the assigned treatment. During the study, researchers will monitor symptom duration, vital signs, and changes in patient care status for up to 28 days. They will also assess overall clinical outcomes, symptom resolution, quality of life impacts on the family, time to return to normal daily activities, and the development of any complications related to the infection. Follow-up includes clinical examinations and parent reports to track progress and safety throughout the study period.
Actively Recruiting
Researchers are collecting and evaluating data on various Abbott vascular medical devices used in clinical procedures. This prospective, non-randomized, open-label, multi-center registry aims to confirm the safety and performance of these devices over their expected lifetime. The study also focuses on monitoring risks, detecting new risks based on real evidence, ensuring the benefit-risk balance remains acceptable, and identifying any misuse or off-label use to verify appropriate device use. Participants receive one or more Abbott vascular devices, such as coronary and peripheral stents, pacing catheters, vascular plugs, measurement and imaging tools including FFR and OCT, peripheral and coronary dilatation catheters, guidewires, vessel closure or compression devices, and vascular access introducers. The study covers multiple device types used during vascular procedures performed as part of routine clinical care. During the study, researchers collect clinical data throughout and after the procedures, monitoring outcomes like death, myocardial infarction, target lesion revascularization, amputations, procedural complications, device success, and safety issues. Follow-up assessments occur at procedure time, 30 days, and 12 months to evaluate these outcomes. Participants are followed according to the specified schedule, which may include data collection on clinical events and device performance over time.
Actively Recruiting
This research aims to better understand how advance directives are used and implemented in the intensive care unit ICU and how they affect patient outcomes. The study focuses on adult patients treated in the ICU at the University Hospital Basel between 2011 and 2023. It compares outcomes such as survival, neurological function recovery, and Glasgow Outcome Score between patients with and without advance directives. The study involves collecting health-related personal data from digital medical records of all eligible adult ICU patients during the specified period. Extracted data include patient characteristics, hospitalization details, presence and content of advance directives, clinical information, treatments received, and outcomes at discharge. This observational study does not involve administering any treatment but analyzes existing data retrospectively. Participants involvement is limited to data collection from their medical records. Researchers will analyze the proportion of patients with advance directives and how these directives are applied in clinical practice. Outcomes measured include survival rates, neurological recovery, and Glasgow Outcome Scores at hospital discharge. The study covers data from 2011 through 2023, with the study completion expected by December 2050.
Actively Recruiting
This research aims to understand how follow-up care is managed for survivors of childhood cancer in Switzerland as they move from pediatric to adult healthcare. It focuses on adolescent and young adult survivors who have completed cancer treatment and are living with potential late effects. The study compares three different transition models to find out which best meets survivors needs and helps maintain regular follow-up care. Participants are part of a multicenter study involving three pediatric oncology centers in Switzerland. Survivors receive questionnaires about their cancer knowledge, worries, self-management skills, ongoing care, and expectations related to their follow-up care. Questionnaires are sent before and after their transition to adult care, with follow-ups at three and fifteen months to track changes over time. During the study, participants complete several questionnaires assessing their readiness for transition and knowledge about their cancer history. The study measures cancer worry, self-management, ongoing care needs, and expectations at baseline, three months, and fifteen months. Data helps improve transition strategies, aiming for better adherence to adult follow-up care. The total participation time covers these assessments over more than a year, supporting long-term survivor care.
1-10 of 87
1